title: [Standard and new regimens of anticoagulation for pulmonary thromboembolism].
abstract: The article discusses various options of anticoagulant therapy for pulmonary thromboembolism and the main criteria of medication choice including the use of unfractionated heparin, low-molecular-weight heparins, and rivaroxaban. The data presented are based on the own experience and results of international clinical trials.
authors.forename: Iu L
authors.initials: IuL
authors.lastname: Shevchenko
authors.forename: Iu M
authors.initials: IuM
authors.lastname: Stoĭko
authors.forename: M N
authors.initials: MN
authors.lastname: Zamiatin
authors.forename: E D
authors.initials: ED
authors.lastname: Kartasheva
mesh_terms: D000925:Anticoagulants / Q000145:classification / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology / Q000517:prevention & control; D006493:Heparin / Q000494:pharmacology; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology; D006801:Humans; D009025:Morpholines / Q000494:pharmacology; D017063:Outcome Assessment, Health Care; D018579:Patient Selection; D011655:Pulmonary Embolism / Q000097:blood / Q000188:drug therapy; D020379:Risk Adjustment; D000069552:Rivaroxaban; D013876:Thiophenes / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D009025:Morpholines; D013876:Thiophenes; D006493:Heparin; D000069552:Rivaroxaban